ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 173 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2019. The put-call ratio across all filers is 6.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $13,000 | +85.7% | 279 | +68.1% | 0.00% | – |
| Q3 2019 | $7,000 | -36.4% | 166 | 0.0% | 0.00% | – |
| Q2 2019 | $11,000 | +57.1% | 166 | +67.7% | 0.00% | – |
| Q1 2019 | $7,000 | +40.0% | 99 | 0.0% | 0.00% | – |
| Q4 2018 | $5,000 | +400.0% | 99 | +330.4% | 0.00% | – |
| Q2 2018 | $1,000 | 0.0% | 23 | 0.0% | 0.00% | – |
| Q1 2018 | $1,000 | -99.3% | 23 | -99.3% | 0.00% | -100.0% |
| Q4 2017 | $152,000 | +1069.2% | 3,273 | +1246.9% | 0.00% | – |
| Q3 2017 | $13,000 | +333.3% | 243 | +465.1% | 0.00% | – |
| Q2 2017 | $3,000 | -70.0% | 43 | -69.9% | 0.00% | – |
| Q1 2017 | $10,000 | -16.7% | 143 | -10.1% | 0.00% | – |
| Q4 2016 | $12,000 | +140.0% | 159 | +169.5% | 0.00% | – |
| Q3 2016 | $5,000 | – | 59 | +883.3% | 0.00% | – |
| Q2 2016 | $0 | – | 6 | 0.0% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 6 | -50.0% | 0.00% | – |
| Q4 2015 | $1,000 | 0.0% | 12 | 0.0% | 0.00% | – |
| Q3 2015 | $1,000 | – | 12 | +50.0% | 0.00% | – |
| Q3 2014 | $0 | – | 8 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |